

2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Treo Ventures IIFiled to raise in 2022, with no closing reported yet. | 2022 | $150M | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Brad Vale | Quiet | Medical devices, Biotech & pharma | 3 | 0 |
| Mudit Jain | Quiet | Medical devices | 9 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of Treo Ventures’s own portfolio companies, based on 11 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Treo Ventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Hatteras Venture Partners | 3 | Avivomed, iVEAcare, NeuroTronik |
| U.S Venture Partners | 3 | Inspire Medical Systems, NEOCHORD, ShiraTronics |
| Vensana Capital | 2 | CVRx, iVEAcare |
| Versant Venture Capital | 2 | CVRx, iVEAcare |
| Baird Venture Partners | 1 | NEOCHORD |
| BioStar Ventures | 1 | NEOCHORD |
| Osage University Partners | 1 | Hyalex Orthopaedics |
| OUP | 1 | Hyalex Orthopaedics |
A shared board seat: a company where filings name a Treo Ventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.